Maximizing neuroprotection: where do we stand?

被引:11
|
作者
Kuffler, Damien P. [1 ]
机构
[1] Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA
来源
THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2012年 / 8卷
关键词
adenosine; hypothermia; alkalinization; glucocorticoids; SPINAL-CORD-INJURY; RETROGRADE VENOUS PERFUSION; ADENOSINE A(2A) AGONIST; CULTURED HIPPOCAMPAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; RAT SENSORY NEURONS; CELL-DEATH; IN-VITRO; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA;
D O I
10.2147/TCRM.S16196
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Brain and spinal cord traumas include blunt and penetrating trauma, disease, and required surgery. Such traumas trigger events such as inflammation, infiltration of inflammatory and other cells, oxidative stress, acidification, excitotoxicity, ischemia, and the loss of calcium homeostasis, all of which cause neurotoxicity and neuron death. To prevent trauma-induced neurological deficits and death, each of the many neurotoxic events that occur in parallel or sequentially must be minimized or prevented. Although neuroprotective techniques have been developed that block single neurotoxic events, most provide only limited neuroprotection and are only applied singly. However, because many neurotoxicity triggers arise from common events, an approach for invoking more effective neuroprotection is to apply multiple neuroprotective methods simultaneously before the many neurotoxic triggers and cascades are initiated and become irreversible. This paper first discusses some triggers of neurotoxicity and neuroprotective mechanisms that block them, including hypothermia, alkalinization, and the administration of adenosine. It then examines how the simultaneous application of these techniques provides significantly greater neuroprotection than is provided by any technique alone. The paper also stresses the importance of determining whether the neuroprotection provided by these techniques can be further enhanced by combining them with additional techniques, such as the systemic administration of glucocorticoids. Finally, the paper stresses the absolute critical importance of applying these techniques within the "golden hour" following trauma, before the many neurotoxic events and cascades are manifest and before the neurotoxic cascades become irreversible.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 50 条
  • [31] Intra-tumoral susceptibility signals in brain gliomas: where do we stand?
    Cataldi, Simone
    Feraco, Paola
    Marrale, Maurizio
    Alongi, Pierpaolo
    Geraci, Laura
    Grutta, Ludovico La
    Caruso, Giuseppe
    Bartolotta, Tommaso Vincenzo
    Midiri, Massimo
    Gagliardo, Cesare
    FRONTIERS IN RADIOLOGY, 2025, 5
  • [32] Kisspeptin and neurokinin B analogs use in gynecological endocrinology: where do we stand?
    Szeliga, A.
    Podfigurna, A.
    Bala, G.
    Meczekalski, B.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2020, 43 (05) : 555 - 561
  • [33] Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?
    Ntenti, Charikleia
    Lallas, Konstantinos
    Papazisis, Georgios
    DIAGNOSTICS, 2023, 13 (11)
  • [34] Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand?
    Ferlazzo, Nadia
    Cirmi, Santa
    Calapai, Gioacchino
    Ventura-Spagnolo, Elvira
    Gangemi, Sebastiano
    Navarra, Michele
    MOLECULES, 2016, 21 (10):
  • [35] Pharmacological interventions for spinal cord injury: Where do we stand? How might we step forward?
    Rabchevsky, Alexander G.
    Patel, Samir P.
    Springer, Joe E.
    PHARMACOLOGY & THERAPEUTICS, 2011, 132 (01) : 15 - 29
  • [36] Therapeutic Hypothermia for Brain Ischemia Where Have We Come and Where Do We Go?
    Yenari, Midori A.
    Hemmen, Thomas M.
    STROKE, 2010, 41 (10) : S72 - S74
  • [37] Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?
    Stelitano, Giovanni
    Cocorullo, Mario
    Mori, Matteo
    Villa, Stefania
    Meneghetti, Fiorella
    Chiarelli, Laurent Roberto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [38] Cardioprotective Utility of Urocortin in Myocardial Ischemia-Reperfusion Injury: Where do We Stand?
    Basman, Craig
    Agrawal, Pratik
    Knight, Richard
    Saravolatz, Louis
    Mcree, Chad
    Chen-Scarabelli, Carol
    Narula, Jagat
    Scarabelli, Tiziano
    CURRENT MOLECULAR PHARMACOLOGY, 2018, 11 (01) : 32 - 38
  • [39] Autophagic flux control in neurodegeneration: Progress and precision targeting-Where do we stand?
    Lumkwana, Dumisile
    du Toit, Andre
    Kinnear, Craig
    Loos, Ben
    PROGRESS IN NEUROBIOLOGY, 2017, 153 : 64 - 85
  • [40] Herbal drugs-loaded soft nanoparticles for treating skin disorders: Where do we stand?
    Reolon, Jessica Brandao
    Sari, Marcel Henrique Marcondes
    Marchiori, Crisleine
    Dallabrida, Kamila Gabrieli
    dos Santos, Jaqueline Aparecida Rodrigues
    de Almeida, Isabela de Fatima Ramos
    Alves, Fernando Miguel Stelmach
    Bonini, Juliana Sartori
    Ferreira, Luana Mota
    INDUSTRIAL CROPS AND PRODUCTS, 2023, 206